Atrium Therapeutics, Inc. Common Stock (RNA) — Capital Reinvestment Ratio
Atrium Therapeutics, Inc. Common Stock (RNA) has a Capital Reinvestment Ratio of 0.05x as of December 2023, meaning it reinvests 0% of its operating cash flow ($16.50 Million) in capital expenditures ($863.00K). Check RNA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Atrium Therapeutics, Inc. Common Stock Capital Reinvestment Ratio (2019–2019)
This chart tracks Atrium Therapeutics, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Atrium Therapeutics, Inc. Common Stock cash conversion from operations.
Annual Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year Capital Reinvestment Ratio for Atrium Therapeutics, Inc. Common Stock from 2019 to 2019. See Atrium Therapeutics, Inc. Common Stock free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 0.09x | $2.49 Million | $235.00K | — |